Interdisciplinary Critique of Sipuleucel-T as immunotherapy in castration-resistant prostate cancer

Journal of the National Cancer Institute

Volumn 104, Issue 4, 2012, Pages 273-279

  Huber, Marie L ^d   Haynes, Laura ^a   Parker, Chris ^b   Iversen, Peter ^c  

^a TRUDEAU INSTITUTE   (United States)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ATRASENTAN; DOCETAXEL; MITOXANTRONE; PLACEBO; PREDNISONE; SIPULEUCEL T; ZIBOTENTAN; ZOLEDRONIC ACID;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DRUG EFFICACY; DRUG SAFETY; HUMAN; OVERALL SURVIVAL; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW;

AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PATIENT SELECTION; PROGNOSIS; PROSTATIC NEOPLASMS; PROTEIN TYROSINE PHOSPHATASES; RESEARCH DESIGN; SURVIVAL ANALYSIS; TISSUE EXTRACTS;

EID: 84857397717     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr514     Document Type: Review

References (49)

1. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New Engl J Med. 2010; 363 (5): 411-422.
2. Longo D. New therapies for castration-resistant prostate cancer. New Engl J Med. 2010; 363 (5): 479-481.
3. March 2007 CTGT Advisory Committee Meeting FDA CMC Presentation, Slides 4 & 11. www.fda.gov/ohrms/dockets/ac/07/slides/2007-4291S1-2.ppt. Accessed December 3, 2011.
4. March 2007 CTGT Advisory Committee Meeting CMC Briefing Document. http: //www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4291B1-04a.pdf. Accessed December 3, 2011.
5. Wonnacott K, Moos M, Husain S, Finn T. CMC Review, BLA 125197, Sipuleucel-T. http: //www.fda.gov/downloads/BiologicsBloodVaccines/ CellularGeneTherapyProducts/ApprovedProducts/UCM214565.pdf. Accessed December 3, 2011.
6. Zhen B, Gupta G. FDA Statistical Review and Evaluation Sipuleucel-T. http: //www.fda.gov/downloads/BiologicsBloodVaccines/ CellularGeneTherapyProducts/ApprovedProducts/UCM214543.pdf. Accessed December 3, 2011. Completed April 30, 2010.
7. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003; 21 (7): 1232-1237. (Pubitemid 46606398)
8. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res. 2007; 13 (21): 6396-6403. (Pubitemid 350075029)
9. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010; 28 (7): 1099-1105.
10. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med. 2004; 351 (15): 1502-1512. (Pubitemid 39315317)
11. Fan C, George B, Bross P. FDA Clinical Review Sipuleucel-T. http: //www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ ApprovedProducts/UCM214540.pdf. Accessed December 3, 2011. Completed April 28, 2010.
12. Burns EA, Lum LG, L'Hommedieu G, Goodwin JS. Specific humoral immunity in the elderly: in vivo and in vitro response to vaccination. J Gerontol. 1993; 48 (6): B231-B236. (Pubitemid 23333632)
13. Grubeck-Loebenstein B. Fading immune protection in old age: vaccination in the elderly. J Comp Pathol. 2010; 142 (suppl 1): s116-s119.
14. Gravekamp C. The importance of the age factor in cancer vaccination at older age. Cancer Immunol Immunother. 2009; 58 (12): 1969-1977.
15. Pawelec G, Lustgarten J, Ruby C, Gravekamp C. Impact of aging on cancer immunity and immunotherapy. Cancer Immunol Immunother. 2009; 58 (12): 1907-1908.
16. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94 (19): 1458-1468.
17. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008; 26 (2): 242-245.
18. Higano C, Saad F, Somer B, et al. A phase 3 trial of GVAX immuno-therapy for prostate cancer versus docetaxel plus prednisone in asymptom-atic, castrationresistant prostate cancer (CRPC). Presented at the 2009 Genitourinary Cancers Symposium; February 26-28, 2009; Orlando, FL. Abstract LBA150. http: //www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst-detail- view&confID=64&abstractID=20543. Accessed December 3, 2011.
19. Carducci MA, Saad F, Abrahamsson PA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with meta-static hormone-refractory prostate cancer. Cancer. 2007; 110 (9): 1959-1966. (Pubitemid 350036854)
20. James ND, Caty A, Payne H, et al. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized phase II trial. BJU Int. 2010; 106 (7): 966-973.
21. Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L. Phase 3 study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol. 2002; 168 (6): 2439-2443. (Pubitemid 35402635)
22. Small EJ, Fong L. Developing immunotherapy as legitimate therapy for patients with prostate cancer. J Clin Oncol. 2010; 28 (7): 1085-1087.
23. Kantoff PW. Updated results of the IMPACT trial of sipuleucel-T for metastatic, castration-resistant prostate cancer. Presentation at the ASCO Genitourinary Cancers Symposium; March 5-7, 2010; San Francisco, CA.
24. Berthold DR, Pond GR, Roessner M, et al. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate specific antigen, pain, and quality of life response and survival in the TAX-327 Study. Clin Cancer Res. 2008; 14 (9): 2763-2767.
25. Registry entry for first Phase III sipuleucel-T trial D9901 (n=127). http: //clinicaltrials.gov/ct2/show/NCT00005947. Accessed December 3, 2011.
26. Small EJ, Reese DM, Um B, et al. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 1999; 5 (7): 1738-1744. (Pubitemid 29334454)
27. Aspinall R, Del Giudice G, Effros R, Grubeck-Loebenstein B, Sambhara S. Challenges for vaccination in the elderly. Immun Ageing. 2007; 4 (1): 9.
28. Hakim FT, Gress RE. Immunosenescence: deficits in adaptive immunity in the elderly. Tissue Antigens. 2007; 70 (3): 179-189. (Pubitemid 47106657)
29. Goronzy JJ, Weyand CM. T cell development and receptor diversity during aging. Curr Opin Immunol. 2005; 17 (5): 468-475. (Pubitemid 41207948)
30. Goronzy JJ, Lee WW, Weyand CM. Aging and T-cell diversity. Exp Gerontol. 2007; 42 (5): 400-406. (Pubitemid 46561179)
31. Schindowski K, Fröhlich L, Maurer K, Müller WE, Eckert A. Age-related impairment of human T lymphocytes' activation: specific differences between CD4 (+) and CD8 (+) subsets. Mech Ageing Dev. 2002; 123 (4): 375-390. (Pubitemid 34024925)
32. Song L, Kim Y, Chopra R, et al. Age-related effects in T cell activation and proliferation. Exp Gerontol. 1993; 28 (4-5): 313-321. (Pubitemid 23226549)
33. Borrego F, Alonso MC, Galiani MD. NK phenotypic markers and IL2 response in NK cells from elderly people. Exp Gerontol. 1999; 34 (2): 253-265. (Pubitemid 29153022)
34. Kiertscher S, Luo J, Dubinett SM, Roth MD. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol. 2000; 164 (3): 1269-1276. (Pubitemid 30067239)
35. Della Bella S, Bierti L, Presicce P, et al. Peripheral blood dendritic cells and monocyte are differently regulated in elderly. Clin Immunol. 2007; 122 (2): 220-228. (Pubitemid 46073895)
36. Lazuardi L, Jenewein B, Wolf AM, Pfister G, Tzankov A, Grubeck-Loebenstein B. Age-related loss of naïve T cells and dysregulation of T cell/B cell interactions in human lymph nodes. Immunology. 2005; 114 (1): 37-43. (Pubitemid 40030291)
37. Mo R, Chen J, Han Y. T cell chemokine receptor expression in aging. J Immunol. 2003; 170 (2): 895-904. (Pubitemid 36070543)
38. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordi-nated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol. 2006; 80 (2): 227-236. (Pubitemid 44835496)
39. Blankenstein T. The role of tumor stroma in the interaction between tumor and immune system. Curr Opin Immunol. 2005; 17 (2): 180-186. (Pubitemid 40343106)
40. Taub D, Longo D. Insights into thymic aging and regeneration. Immunol Rev. 2005; 205 (1): 72-93. (Pubitemid 40780178)
41. Fulop T, Kotb R, Fortin CF, Pawelec G, de Angelis F, Larbi A. Potential role of immunosenescence in cancer development. Ann N Y Acad Sci. 2010; 1197 (1): 158-165.
42. Malaguarnera L, Ferlito L, Di Mauro S, Imbesi RM, Scalia G, Malaguarnera M. Immunosenescence and cancer: a review. Arch Gerontol Geriatr. 2001; 32 (2): 77-93. (Pubitemid 32335564)
43. Dominguez AL, Lustgarten J. Implications of aging and self-tolerance on the generation of immune and antitumor immune responses. Cancer Res. 2008; 68 (13): 5423-5431.
44. Zhang HG, Grizzle WE. Aging, immunity, and tumor susceptibility. Immunol Allergy Clin North Am. 2003; 23 (1): 83-102. (Pubitemid 36268306)
45. Cambier J. Immunosenescence: a problem of lymphopoiesis, homeostasis, microenvironment, and signaling. Immunol Rev. 2005; 205 (1): 5-6.
46. Naylor K, Li G, Vallejo AN, et al. The influence of age on T cell generation and TCR diversity. J Immunol. 2005; 174 (11): 7446-7452. (Pubitemid 40705717)
47. Cicin-Sain L, Smyk-Pearson S, Currier N, et al. Loss of naive T cells and repertoire constriction predict poor response to vaccination in old primates. J Immunol. 2010; 184 (12): 6739-6745.
48. Mackall CL, Hakim FT, Gress RE. Restoration of T-cell homeostasis after T-cell depletion. Semin Immunol. 1997; 9 (6): 339-346. (Pubitemid 28021491)
49. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005; 23 (10): 2346-2357. (Pubitemid 46218728)